Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack patients monitored for hidden rhythm disorder

NCT ID NCT04528511

Knowledge-focused Sponsor: Shanghai 10th People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 774 adults who develop a new type of irregular heartbeat (atrial fibrillation) while hospitalized for a heart attack. Researchers will use continuous electronic monitoring to measure how much time patients spend in this abnormal rhythm. The goal is to see if the amount of irregular rhythm predicts future health problems like death or heart failure, and to help doctors decide who needs blood thinners.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict complications and guide blood-thinner use in heart attack patients who develop atrial fibrillation.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly test a new therapy. Results may only show associations, not cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 774 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with AMI who do not have a medical history of AF and develop an incident AF episode during the index hospitalization.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (\>18 years old); * Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization; * Patients must have received in-hospital CEM for at least 5 days; * Patients must give informed consent. Exclusion Criteria: * Patients with a medical history of pre-existing AF; * Patients with a medical history of rheumatic valvular disease; * Patients with a medical history of sick sinus syndrome; * Patients undergoing emergent coronary artery bypass surgery; * Patients who suffer malignant tumors with an expected lifetime less than 1 year ; * Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved; * Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI; * Patients who have died during the index hospitalization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction Atrial fibrillation new onset

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Cardiology, Shanghai Tenth People's Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200072, China

  • Kaifeng Central Hospital

    RECRUITING

    Kaifeng, Henan, China

  • Luoyang Central Hospital

    RECRUITING

    Luoyang, Henan, China

  • Shanghai Seventh People's Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.